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Drug discovery programs sponsored by public or private initiatives pursue the same ambitious goal: a
crushing defeat of major Neglected Tropical Diseases (NTDs) during this decade. Both target-based and
target-free screenings have pros and cons when it comes to ﬁnding potential small-molecule leads among
chemical libraries consisting of myriads of compounds. Within the target-based strategy, crystals of
pathogen recombinant-proteins are being used to obtain three-dimensional (3D) structures in silico for
the discovery of structure-based inhibitors. On the other hand, genetically modiﬁed parasites expressing
easily detectable reporters are in the pipeline of target-free (phenotypic) screenings. Furthermore, lead
compounds can be scaled up to in vivo preclinical trials using rodent models of infection monitoring
parasite loads by means of cutting-edge bioimaging devices. As such, those preferred are ﬂuorescent and
bioluminescent readouts due to their reproducibility and rapidity, which reduces the number of animals
used in the trials and allows for an earlier stage detection of the infective process as comparedwith classical
methods. In this review, we focus on the current differences between target-based and phenotypic screen-
ings in Leishmania, as an approach that leads to the discovery of new potential drugs against leishmaniasis.
 2014 The Authors. Published by Elsevier Ltd. on behalf of Australian Society for Parasitology Inc. This is
an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
Leishmania is a heteroxenous parasite, either as a motile
promastigote form developing in sandﬂy guts or as a non-motile
intracellular amastigote form in the deﬁnitive host macrophages.
The different manifestations of leishmaniasis are always linked to
the marginal poorest sectors of the population from low-income
countries. Yet no effective vaccine has so far been developed and,
moreover, current pharmacological treatments are toxic, expensive
or require intravenous administration, which hinders patient treat-
ment adherence. Although recent initiatives have improved the
antileishmanial drug vademecum combining current medicines or
reproﬁling others, there is more than ever an urgent need to
discover new antileishmanial drugs that could be translated into
clinical practice (Croft and Olliaro, 2011). One of the hot issues of
the last 4th Zing Drug Discovery Conference held in Nerja (Spain),
hosted by Prof. Peter J. Myler (Seattle Biomedical Research Institute,
WA, USA) and Prof. Babu L. Tekwani (National Center for NaturalProducts Research, Oxford MS, USA), was the limited agreement
found between the results obtained from target-based and target-
free (phenotypic) screenings in Leishmania. On the one hand, in
silico target identiﬁcation for structure-based drug discovery
should be conﬁrmed by further in vitro biochemical studies. On
the other hand, in vitro phenotypic screenings allow identifying
hit compounds eliminating the parasite regardless of their
mechanism of action. These different screening approaches were
brought forward and discussed there, highlighting the use of
bioimaging readouts to test small-molecule libraries. However,
some discrepancies arose when comparing the inhibition of speciﬁc
targets with their respective antileishmanial effect.2. Target-based screenings
Small-molecule target-based screenings are designed to disrupt
speciﬁc proteins that: (i) are essential for parasite survival and (ii)
are either absent from, or structurally dissimilar to those occurring
in the host. The genomic data availability of Leishmania spp. has
enabled the evaluation of several pharmacological targets since
complete genomic sequences allow the identiﬁcation of protein-
coding genes (Ivens et al., 2005). In silico high-throughput virtual
screening and docking procedures using 3D X-ray structured
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approaches to design novel drugs against parasite speciﬁc targets.
In this context, Dr. Myler offered the participants the services
of the Seattle Structural Genomics Centre for Infectious Disease
(SSGCID) funded by the National Institute of Allergy and Infectious
Diseases (NIAID, USA), a facility open to researchers to resolve pro-
tein structures of putative targets from emerging microorganisms
in order to implement a structure-based drug research strategy
(Stacy et al., 2011).
Several attempts have been made to identify essential targets
against Leishmania spp. The Special Programme for Research and
Training in Tropical Diseases (TDR) database, hosted at the World
Health Organization (WHO), provides a bank of potential targets
obtained from biochemical, genetic and pharmacological data of
several well-known pathogens. At the top rank of this list can be
found those targets needed for parasite survival such as trypano-
thione reductase, an enzyme involved in the maintenance of the
parasite’s redox equilibrium (Eberle et al., 2011); dihydrofolate
reductase, required for the de novo synthesis of purines; cysteine
protease B, a stage-regulated virulence factor that is secreted by
the amastigote form to the phagolysosome (Caffrey et al., 2011);
or DNA topoisomerases, whose structure radically differs from that
of the host and which are involved in DNA replication, transcrip-
tion and recombination (Prada et al., 2013). Finally, it is worth
mentioning the LeishDrug network (a FP7 consortium supported
by EU funds), an interdisciplinary approach ready to reveal the role
of protein kinases associated with amastigote virulence in visceral
leishmaniasis (Palmeri et al., 2011).
Nonetheless, target-based screenings are not exempt from
drawbacks. The intracellular amastigote is localized inside the
macrophage parasitophorous vacuole, where the compound must
enter and remain active. Consequently, in order to retain full drug
efﬁcacy, the putative hit should be permeable enough to pass
across several membranes as well as remain stable in an acidic
environment. In addition, it should not be substrate of xenobi-
otic-metabolizing enzymes for both the host and the parasite.
Moreover, many compounds designed against speciﬁc parasite tar-
gets usually present low selectivity. This fact shows that target
exclusiveness in the parasite might be a necessary but not sufﬁ-
cient condition to validation. Therefore, phenotypic screening
stands out as the keystone assay for those studies preceding the
preclinical drug discovery phase.3. Phenotypic screenings (HTS)
There was general agreement at the Conference that there is an
urgent need for a more reliable model of phenotypic in vitro
screening that might mimic as much as possible the real environ-
ment within the deﬁnitive host. Inside the mature parasitophorous
vacuole within the infected macrophage, the pathogen must with-
stand low pH and enhanced oxidative stress. These conditions
could be responsible for the degradation of many drugs. On the
one hand, monoxenous parasites, such as the procyclic blood-
stream forms of Trypanosoma brucei, modiﬁed or not to express
ﬂuorescent or bioluminescent reporters, can serve by themselves
as models for in vitro target-free screening. On the other hand,
stage-speciﬁc drug susceptibilities are commonly described by
researchers in heteroxenous Trypanosoma cruzi and Leishmania
spp. parasites. In vitro Leishmania free-living promastigotes are
easy to culture and handle, but they represent the insect stage of
the parasite life cycle. It has been suggested that only 4% of the hits
identiﬁed by using Leishmania promastigotes have some effect on
intracellular amastigote forms (Freitas-Junior et al., 2012). There-
fore, an amastigote-based phenotypic screening is reinforced as
the most suitable approach to be developed. According to thisassumption, thousands of compounds were tested against Leish-
mania spp. and T. cruzi on axenic amastigotes, due to their easy
handling and cultivation in the absence of host cells (Bustamante
et al., 2011). Nevertheless, axenic amastigotes present markedly
different gene-expression proﬁles as compared with lesion-derived
amastigotes (Holzer et al., 2006). To this end, phenotypic HTS for
antileishmanial drug discovery should be carried out in intracellu-
lar amastigotes only. In this context, the use of monocytic cell lines
appears to be as an interesting although technically challenging
alternative to perform phenotypic HTS in Leishmania. The human
acute monocytic leukemia cell line (THP-1) has permitted to
screen up to 300,000 compounds from different libraries, obtaining
350 hits that kill the parasite at concentrations below 10 lM
using a High Content Screening (HCS) image-based readout
(Siqueira-Neto et al., 2012).4. Ex vivo murine explants as a model of phenotypic screening
An exciting approach that is midway between in vitro infections
with human THP-1 cells and experimental infections in mice con-
sists in the use of ex vivo explants of Leishmania-infected organs.
Rodents are experimentally infected with ﬂuorescent or biolumi-
nescent Leishmania strains. Once the infection is established, tar-
get-infected organs are harvested in order to develop the ex vivo
explant culture. It is of paramount importance that genetic manip-
ulation does not alter the virulence of transgenic strains, so that
they are able to develop the disease in the same conditions as
wild-type parasites. Rodent visceral leishmaniasis results in a
marked splenomegaly, whilst lymphadenopathy prevails in cuta-
neous infections. BALB/c mice are susceptible to reproduce acute
visceral and cutaneous leishmaniasis by Leishmania infantum and
Leishmania major, respectively, developing an adaptative Th2
immune response. For its part, the hamster is the preferred animal
to develop a chronic infection model of visceral leishmaniasis by
Leishmania donovani. Splenic or lymph node ex vivo infected
explants show advantages over in vitro systems, because they
include the whole cellular population involved in the host-parasite
interaction: macrophages, CD3+ and CD4+ T cells, B lymphocytes
and granulocytes; which could affect the therapeutic effect of the
tested compound. In addition, the number of animals used in these
trials can be drastically reduced, since a single infected spleen can
yield up to four 96-well plates, thus enabling the evaluation of sev-
eral collections of small molecules at a single dose.
This approach was successfully validated by Dr. Melby’s group
in the University of Texas Medical Branch at Galveston (TX, USA).
They performed a single-dose concentration screening of four
small-molecule libraries containing 4035 compounds. The spleens
from hamsters infected with a luciferase-transfected L. donovani
strain served to detect more than two hundred hits under a
96-well plate format (Osorio et al., 2011). The validation of a lymph
node ex vivo explant model has been recently published; in this
case, a L. major strain was transfected with the same biolumines-
cent reporter (Peniche et al., 2014). However, one of the main dis-
advantages of bioluminescence is the need for cell lysis prior to the
addition of a light-emitting substrate and subsequent plate read-
out. This time-consuming step can be avoided by using ﬂuorescent
proteins that signiﬁcantly reduce time and cost of the screening
(Calvo-Álvarez et al., 2012).5. Towards preclinical in vivo models
Fluorescent or bioluminescent transfected parasites are indeed
a step forward towards identifying lead compounds in in vivo
models; thus reducing the number of animals to be used. In vivo
real-time imaging systems allow the acquisition of ﬂuorescent or
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internal organs. Both bioluminescent parasites, which require the
parenteral administration of light-emitting substrates, and ﬂuores-
cent ones permit the appraisal of the infection by recording ﬂuo-
rescent or bioluminescent signals prior to the visual appearance
of the clinical symptoms.
In regard to visceral models, bioluminescence has advantages
over ﬂuorescence due to the poor penetration of excitation light
by ﬂuorescent proteins and tissue autoﬂuorescence. Even so, trans-
genic parasites overexpressing ﬂuorescent proteins would be more
appropriate models in order to develop cutaneous or mucocutane-
ous infections in BALB/c mice without the need for a light-emitting
substrate injection. Alternatively, infrared ﬂuorescent proteinswith
excitation/emissionwavelengths between650 and 900 nmcould be
suitable for whole-body imaging given that such wavelengths pen-
etrate tissue well and minimize the absorbance by haemoglobin,
water and lipids as well as light scattering, as previously reported
for viral infections (Shu et al., 2009). Finally, the use of humanized
murinemodels, which are being developed nowadays against other
diseases (Rochford et al., 2013), could becomean area of rising inter-
est to explore cutaneous leishmaniasis in the near future.
6. Summary
Public and private initiatives are supporting the discovery of
novel chemotherapeutic treatments to eliminate NTDs by this
decade. This ambitious proposal has permitted researchers to
access a vast collection of compounds that can be tested and
screened. The main objective of this ﬁrst drug-screening phase is
to ﬁnd small-molecules with optimal selective indexes for a given
pathogen that guarantee good results in a preclinical model of the
disease. However, there is a lack of predictive in vitro models that
permit achieving potency, speciﬁcity and safety goals, as well as a
good compliance with Lipinski’s rules for further in vivo studies.
Researchers often complain about great hit molecules selected in
target-based screenings that fail in target binding because of poor
permeability, degradation into inactive metabolites by microsomal
enzymes or inadequate host immune response.
In order to avoid a discussion going round in circles, target-free
HTS appears as the most promising method to discover drugs
under a ‘‘hit to lead’’ strategy, although there is still a long way
to go. For this purpose, it is necessary to ﬁnd a uniﬁed screening
model that uses the parasite forms that actually interact with the
deﬁnitive host cells, so as to substitute others that use artiﬁcially-
created axenic parasites under laboratory conditions.
In this context, optimized phenotypic assays resembling the
pathophysiological environment of infected spleens and lymph
nodes, combined with cutting-edge bioimaging devices, could
become a promising ex vivo system to screen libraries of small-
molecules against Leishmania.
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